Cardiol Therapeutics (TSE:CRDL) Sets New 52-Week Low – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as C$1.48 and last traded at C$1.57, with a volume of 60153 shares changing hands. The stock had previously closed at C$1.57.

Cardiol Therapeutics Stock Performance

The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The company has a market cap of C$135.26 million, a P/E ratio of -3.20 and a beta of 0.70. The stock’s fifty day moving average price is C$1.85 and its two-hundred day moving average price is C$2.30.

Insiders Place Their Bets

In related news, Director David Elsley purchased 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were bought at an average cost of C$1.88 per share, with a total value of C$75,072.00. Also, Senior Officer Guillermo Torre acquired 17,240 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average price of C$1.81 per share, with a total value of C$31,277.77. Insiders acquired 86,140 shares of company stock worth $161,456 over the last three months. Insiders own 4.57% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.